Abstract
The high mortality associated with current therapeutic approaches to nosocomial pneumonia has motivated consideration of newer immunologic approaches to prevention or therapy of this infection. Serotype specific vaccines, hyperimmune immunoglobulins, and monoclonal antibodies have been developed for certain problematic pathogens.Pseudomonas aeruginosa has been the major focus of this approach, and trials of hyperimmune anti-Ps. aeruginosa globulins for treatment of pneumonia are underway. Broad-spectrum, anti-lipopolysaccharide antibody preparations have also been employed for prophylaxis of nosocomial pneumonia, but to date these trials have not been successful. Finally, anticytokine antibody therapy to reduce infection-initiated inflammatory lung damage is under consideration.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Pennington JE (1988) Impact of molecular biology onPseudomonas aeruginosa immunization. J Hosp Infect 11 [Suppl A]: 96–102
Pennington JE, Menkes E (1981) Type-specific versus cross-protective vaccination for gram-negative pneumonia. J Infect Dis 144:599–603
Klick JM, DuMoulin GC, Hedley-White J et al (1975) Prevention of gram-negative bacillary pneumonia using polymyxin aerosol as prophylaxis II effect on the incidence of pneumonia in seriously ill patients. J Clin Invest 55:514–519
Pennington JE (1990)Pseudomonas aeruginosa immunotherapy. Eur J Clin Microbiol Infect Dis 9:377–380
Reynolds HY (1989) Normal and defective respiratory host defenses. In: Pennington JE (ed) Respiratory infections: diagnosis and management, 2nd ed. Raven Press, New York, pp 1–33
Toews GB (1989) Pulmonary clearance of infectious agents. In: Pennington JE (ed) Respiratory infections: diagnosis and management, 2nd edn. Raven Press, New York, pp 41–51
Woods DE (1989) Bacterial colonization of the respiratory tract: clinical significance. In: Pennington JE (ed) Respiratory infections: diagnosis and management, 2nd edn. Raven Press, New York, pp 34–40
Polk HC Jr, Borden S, Aldrett JA (1973) Prevention ofPseudomonas respiratory infection in a surgical intensive care unit. Ann Surg 177:607–615
Collins MS, Roby ME (1984) Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens ofPseudomonas aeruginosa. Am J Med 76:168–174
Class I, Junginger W, Klöss Th (1987) Einsatz vonPseudomonas-immunglobulin bei beatmeten Patienten einer interdisziplinären chirurgischen Intensivstation. Infection 15 [Suppl 2]:67–70
Pennington JE, Pier GB, Small GJ (1986) Efficacy of intravenous immune globulin for treatment of experimentalPseudomonas aeruginosa pneumonia. J Crit Care 1:4–10
Hector RF, Collins MS, Pennington JE (1989) Treatment of experimentalPseudomonas aeruginosa pneumonia with a human IgM monoclonal antibody. J Infect Dis 160:483–489
Saravolatz L, Markowitz N, Collins M, Bogdanoff D, Pennington J (1991) Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and nonseptic patients. J Infect Dis 164:803–806
Baumgartner JD (1990) Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock. Eur J Clin Microbiol Infect Dis 9:711–716
Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, vanMelle G, Klauber MR, Vogt M, Muchlen E, Lüthy R, Chiolero R, Geroulanos S (1985) Prevention of gram-negative shock and death in surgical patients by prophylactic antibody to endotoxin core glycolipid. Lancet II:59–63
Cometta A, Baumgartner JD, Lee M, Glauser MP, and the Anti-Core LPS IVIG collaborative study group (1990) Prophylaxis of infection in high risk surgical patients (pat) with standard intravenous immunoglobulin G (St-IVIG) or with antibody to core glycolipid (Co-IVIG). 30th Interscience Conference Antimicrobial Agents and Chemotherapy, Atlanta, No. 476
Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF (1990) Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am Rev Respir Dis 141:94–97
Roten R, Markert M, Feihl F, Schaller M-D, Tagan M-C, Perret C (1991) Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome. Am Rev Respir Dis 143:590–592
Millar AB, Singer M, Meager A, Foler NM, Johnson NMcI, Rook GAW (1989) Tumour necrosis factor in bronchopulmonary secretions of patients with adult respiratory distress syndrome. Lancet II:712–4
Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–664
Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR (1989) Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 159:189–194
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pennington, J.E. Immunological perspectives in prevention and treatment of nosocomial pneumonia. Intensive Care Med 18 (Suppl 1), S35–S38 (1992). https://doi.org/10.1007/BF01752975
Issue Date:
DOI: https://doi.org/10.1007/BF01752975